HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coal tar safety

This article was originally published in The Rose Sheet

Executive Summary

FDA asked to conduct "formal review" of coal tar use in shampoo, soap and ointments by Occupational Knowledge International in a March 6 petition. The agency should "restrict the sales and distribution of these products to prescription sales," the group states. As a "known carcinogen," coal tar "labeling requirements are insufficient and require additional warning to protect public health." Coal tar use in OTC drug products was banned in Germany in 1995 and in the European Union in 1997, the comments point out. Occupational Knowledge International is involved in ongoing litigation with Cal-EPA regarding coal tar safety

You may also be interested in...



Coal tar

Animal data on carcinogenic risk of dandruff shampoo ingredient are insufficient to support a change in OTC monograph status or new labeling warnings, J&J subsidiary Neutrogena asserts in Oct. 24 comments to FDA. Stressing its opposition to restrictions on coal tar-containing OTCs requested by Occupational Knowledge International in a March petition, the T/Gel marketer also notes the research cited by the petitioners examined "coal tar oil, not coal tar" (1"The Rose Sheet" April 3, In Brief). Neutrogena is one of several defendants in the ongoing Prop 65 lawsuit over coal tar in OTCs brought by Occupational Knowledge International and California Attorney General Bill Lockyer

Coal tar

Animal data on carcinogenic risk of dandruff shampoo ingredient are insufficient to support a change in OTC monograph status or new labeling warnings, J&J subsidiary Neutrogena asserts in Oct. 24 comments to FDA. Stressing its opposition to restrictions on coal tar-containing OTCs requested by Occupational Knowledge International in a March petition, the T/Gel marketer also notes the research cited by the petitioners examined "coal tar oil, not coal tar" (1"The Rose Sheet" April 3, In Brief). Neutrogena is one of several defendants in the ongoing Prop 65 lawsuit over coal tar in OTCs brought by Occupational Knowledge International and California Attorney General Bill Lockyer

California Coal Tar Litigation Stay Sought Pending FDA Petition Review

California litigation over the use of coal tar in dandruff shampoos and other OTC drugs should be suspended pending FDA review of the ingredient's safety, drug distributor Bergen Brunswig tells a San Francisco judge.

Related Content

UsernamePublicRestriction

Register

RS007836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel